A5021978160- Cardiac Valve Diseases and Treatments
- Infective Endocarditis Diagnosis and Management
- Aortic Disease and Treatment Approaches
- Cardiac Structural Anomalies and Repair
- Cardiac Arrhythmias and Treatments
- Cardiac, Anesthesia and Surgical Outcomes
- Cardiovascular Function and Risk Factors
- Mechanical Circulatory Support Devices
- Cardiac pacing and defibrillation studies
- Coronary Interventions and Diagnostics
- Health Systems, Economic Evaluations, Quality of Life
- Diagnosis and Treatment of Venous Diseases
- Pulmonary Hypertension Research and Treatments
- Cardiac Imaging and Diagnostics
- Pharmaceutical Economics and Policy
- Venous Thromboembolism Diagnosis and Management
- Cardiomyopathy and Myosin Studies
- Cardiac and Coronary Surgery Techniques
- Heart Failure Treatment and Management
- Antiplatelet Therapy and Cardiovascular Diseases
Hospital Clínico Universitario de Valladolid
2021-2024
Centro de Investigación en Red en Enfermedades Cardiovasculares
2021-2024
Centro de Investigación Biomédica en Red
2021-2024
Society of Interventional Radiology
2021
Universidad de Valladolid
2021
The balloon-expandable Sapien-3 valve demonstrated superior results in terms of residual aortic regurgitation when compared with self-expandable devices. We aimed to compare for the first-time early outcomes transcatheter heart (THV) Myval device.Consecutive real-world patients from nine European institutions symptomatic severe stenosis treated either or THV devices after June 2018 were compared. Early clinical prospectively gathered and blinded analysis 30-day echocardiography was...
We aimed to describe hemodynamic performance and clinical outcomes at 30-day follow-up of the balloon-expandable (BE) Myval transcatheter heart valve (THV) in low-risk patients.The results next-generation BE THV aortic stenosis (AS) patients are still unknown.Retrospective registry performed nine European centers including with low predicted operative mortality risk according Society thoracic surgeons (STS) system for cardiac evaluation (EuroSCORE-II) scores.Between September 2019 February...
Morbidly obese (MO) patients are increasingly undergoing transcatheter aortic valve replacement (TAVR) and surgical (SAVR) for severe stenosis (AS). However, the best therapeutic strategy these remains a matter debate.Our aim was to compare periprocedural mid-term outcomes in MO TAVR versus SAVR.A multicentre retrospective study including consecutive (body mass index ≥40 kg/m2, or ≥35 kg/m2 with obesity-related comorbidities) from 18 centres either (n=860) biological SAVR (n=696) AS...
<h3>Background</h3> The prevalence of morbid obesity (MO) is increasing worldwide and consequently numbers morbidly obese patients are undergoing transcatheter (TAVR) surgical (SAVR) aortic valve replacement for severe stenosis (AS). Currently, no head to randomized data exists inform the optimal treatment strategy in this cohort. We aimed compare periprocedural mid-term outcomes MO TAVR versus SAVR. <h3>Methods</h3> performed a multicentre retrospective study including consecutive (BMI...